A regulatory affairs director at a mid-cap rare disease company opened Nature Reviews Drug Discovery this week and saw a problem. The review mapped mRNA’s expansion beyond vaccines — into enzyme replacement therapy, personalized cancer immunotherapy, and genome-modifying applications — and the technology curves it described are moving faster than her company’s 2028 IND timelines. Her platform isn’t wrong. It may simply be obsolete before it reaches a pivotal trial.
That’s the real signal buried in what looks like a academic science update.
The Platform Is Outrunning the Consensus
The market’s working assumption has been that mRNA is a vaccine platform that got lucky with COVID-19 and now needs to find its next act. That assumption is structurally wrong, and the consequences for how investors and BD teams are pricing non-vaccine mRNA assets are significant. The global mRNA therapeutics market sat at $11.75 billion in 2023 and is projected to reach $31.30 billion by 2030 — a 17% CAGR that cannot be explained by booster uptake alone. The expansion into therapeutic (non-vaccine) categories is what is doing the work.
Consider what is already in clinical development. Moderna’s mRNA-3927, an intravenous mRNA treatment for Propionic Acidemia, is a direct challenge to the protein-based enzyme replacement therapy model that has dominated rare metabolic disease for two decades. The program instructs the body to produce functional enzyme endogenously — eliminating the cold-chain, immunogenicity, and dosing ceiling problems that plague conventional ERT. If that logic holds in pivotal trials, it doesn’t just expand Moderna’s addressable market. It resets the valuation of every protein-based ERT franchise currently trading on long-term revenue assumptions.
The oncology signal is even louder. Moderna and Merck’s five-year follow-up data for intismeran autogene (mRNA-4157/V940) plus pembrolizumab in high-risk Stage III/IV melanoma — presented at the 2025 ASCO Annual Meeting — moved this from a Phase 2b curiosity to a credible registration asset. Five-year data in adjuvant melanoma is the kind of durability signal that changes payer conversations, not just scientific ones.
Who Holds the Leverage — and Who Just Lost It
Moderna and BioNTech sit at the center of this expansion, but their positions are not symmetric. Moderna has made a deliberate bet on therapeutic diversification — mRNA-3927 in metabolic disease, the personalized cancer vaccine franchise — while BioNTech has concentrated more heavily on oncology through its BNT111 and related immuno-oncology pipeline. Both companies are racing against a hard clock: the N1-methyl-pseudouridine modification patent, a foundational IP layer for current mRNA formulations, expires in 2031. That gives five years of meaningful IP-gated exclusivity on the platform before generics-adjacent competition can enter at the formulation level.
Five years sounds like time. It isn’t.
The companies that lose in this transition are the ones that built platform moats around technologies mRNA renders redundant. Protein subunit vaccine developers have already seen one proof point: Novavax’s ResVax failed its Phase 3 Prepare™ trial in RSV maternal immunization, enrolling 4,636 women and missing its primary endpoint — a failure that accelerated the narrative shift toward mRNA and lipid nanoparticle delivery. Conventional ERT franchises face a slower but structurally similar pressure. If mRNA-3927 generates a clean Phase 3 dataset in Propionic Acidemia, every protein-based ERT in methylmalonic acidemia, Pompe disease, or Fabry disease is sitting on a pipeline that acquirers will discount, not premium.
The counterintuitive read here: the companies most threatened are not the ones with no mRNA exposure. They are the ones with partial mRNA exposure — a vaccine program bolted onto a legacy biologics business — because their BD teams will spend the next three years defending existing franchises rather than moving aggressively into therapeutic mRNA. Structural inertia is the real competitive moat for Moderna and BioNTech right now, and most of their mid-cap competitors are providing it for free.
The Decision That Can’t Wait Until 2028
If you are running BD or portfolio strategy at a company with a protein-based rare disease franchise, the review in Nature Reviews Drug Discovery is not background reading. It is a due diligence document. The specific expansion areas flagged — enzyme replacement, cancer immunotherapy, and genome-modifying therapeutics — map almost exactly onto the categories where mid-cap biotechs hold their highest-conviction assets and their most crowded competitive positions.
The FDA’s regulatory precedent is already established. The EUA granted to Pfizer-BioNTech’s mRNA COVID-19 vaccine on December 11, 2020 was the agency’s first affirmative answer to the question of whether mRNA could clear a regulatory bar — and it cleared it under the highest-scrutiny conditions imaginable, with the entire world watching. Every therapeutic mRNA program now operates with that precedent embedded in its regulatory strategy. The FDA is no longer learning the platform. It is applying it.
The forward signal to watch is Moderna’s next data readout on mRNA-3927. A positive Phase 2 efficacy signal in a metabolic rare disease — not a vaccine indication — would be the pivot point that forces every ERT-adjacent portfolio to run a discounted NPV on its protein-based assets. That readout, whenever it lands, will matter more to mid-cap rare disease valuations than any single M&A transaction in the space this year.
References
- Nature Reviews Drug Discovery — “Towards mRNA therapeutics 2.0”
- Grand View Research — “mRNA Therapeutics Market Size and Share Report, 2030” (April 15, 2024)
- Merck — “Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination with KEYTRUDA in High-Risk Stage III/IV Melanoma”
- Propionic Acidemia Foundation — Clinical Trials: mRNA-3927 (Moderna)
- Global Legal Post — “Partial Win for Moderna in COVID-19 Vaccine Patent Battle with Pfizer and BioNTech” (2031 patent expiry, EP’949)
- Novavax — “Topline Results from Phase 3 Prepare™ Trial of ResVax™” (February 28, 2019)
- Pfizer-BioNTech — FDA Emergency Use Authorization Press Release (December 11, 2020)
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
